z-logo
Premium
Circumsporozoite protein of Plasmodium gallinaceum characterized by monoclonal antibodies
Author(s) -
KRETTLI A.U.,
ROCHA E.M.M.,
LOPES J.D.,
CARNEIRO C.R.W.,
KAMBJ K.K.,
COCHRANE A.H.,
NUSSENZWEIG R.S.
Publication year - 1988
Publication title -
parasite immunology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.795
H-Index - 75
eISSN - 1365-3024
pISSN - 0141-9838
DOI - 10.1111/j.1365-3024.1988.tb00240.x
Subject(s) - plasmodium gallinaceum , biology , virology , monoclonal antibody , epitope , circumsporozoite protein , immunofluorescence , antigen , plasmodium berghei , western blot , plasmodium (life cycle) , antibody , microbiology and biotechnology , immunology , parasite hosting , malaria , gametocyte , plasmodium falciparum , biochemistry , world wide web , computer science , gene
Summary Monoclonal antibodies (MoAb) were produced against both salivary gland sporozoites (SGS) and oocyst sporozoites (OS) of Plasmodium gallinaceum , an avian malaria parasite. By indirect immunofluorescence, all of the MoAbs reacted with both SGS and OS of P. gallinaceum and two of the MoAbs cross‐reacted weakly with P. berghei sporozoites. None of the MoAbs reacted with sporozoites of six additional species of mammalian plasmodia. In Western blot analysis of extracts of either SGS or OS of P. gallinaceum , these MoAbs identified two polypeptides with molecular weights of approximately 76000 and 64000 D. The results of a MoAb inhibition of binding assay and a two‐site one‐antibody immunoradiometric assay indicate that the circumsporozoite protein of P. gallinaceum , like those of mammalian malaria parasites, contains a repetitive immunodominant epitope. Two of the anti‐ P. gallinaceum MoAbs were tested in a sporozoite neutralization assay and decreased, but did not abolish, the infectivity of sporozoites for chickens, indicating that the polypeptide of P. gallinaceum identified by immunoblot is probably the protective antigen.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here